Diltiazem induces severe photodistributed hyperpigmentation: Case series, histoimmunopathology, management, and review of the literature

Rao N. Saladi, Steven R. Cohen, Robert G. Phelps, Andrea N. Persaud, Donald Rudikoff

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Diltiazem hydrochloride is a commonly prescribed benzothiazepine calcium channel blocker for the treatment of cardiovascular disease. Recently, 8 cases of diltiazem-induced photodistributed hyperpigmentation occurring predominantly in elderly African American women were reported. Here, we report occurrence for the first time in a light-skinned African American woman and a Hispanic woman. We also report this finding in an African American man. Biopsy specimens of hyperpigmented areas were obtained for histopathologic evaluation and marker studies. Photospectrometry analysis for diltiazem was performed to analyze the photoabsorption properties of this drug. Observations: Routine laboratory examination results were normal in all patients. Serologic test results for antinuclear antibodies, including Sjögren antibodies anti-Ro (SS-A) and anti-La (SS-B), were negative. Histopathologic analysis of the skin biopsy specimens revealed a sparse lichenoid infiltrate, prominent pigmentary incontinence, and numerous melanophages in the dermis. There was no increase in dermal mucin suggestive of lupus. The mononuclear cells in the specimens were strongly positive for CD3, weakly positive for CD68, and either weakly positive or negative for CD79a. All specimens were negative for Alcian blue staining. Photospectrometry analysis of diltiazem showed an absorption range within the UV-B spectrum. Conclusions: Photospectrometry analysis revealed diltiazem could demonstrate a photosensitizing effect within the UV-B range. Discontinuation of therapy with diltiazem is the most effective modality in resolving hyperpigmentation. Avoidance of sun exposure and consistent use of sunscreens and sun-protective clothing are indicated for patients undergoing diltiazem therapy.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalArchives of Dermatology
Volume142
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Hyperpigmentation
Diltiazem
African Americans
Solar System
Protective Clothing
Biopsy
Sunscreening Agents
Alcian Blue
Skin
Photosensitizing Agents
Antinuclear Antibodies
Calcium Channel Blockers
Serologic Tests
Mucins
Dermis
Hispanic Americans
Anti-Idiotypic Antibodies
Cardiovascular Diseases
Therapeutics
Staining and Labeling

ASJC Scopus subject areas

  • Dermatology

Cite this

Diltiazem induces severe photodistributed hyperpigmentation : Case series, histoimmunopathology, management, and review of the literature. / Saladi, Rao N.; Cohen, Steven R.; Phelps, Robert G.; Persaud, Andrea N.; Rudikoff, Donald.

In: Archives of Dermatology, Vol. 142, No. 2, 02.2006, p. 206-210.

Research output: Contribution to journalArticle

Saladi, Rao N. ; Cohen, Steven R. ; Phelps, Robert G. ; Persaud, Andrea N. ; Rudikoff, Donald. / Diltiazem induces severe photodistributed hyperpigmentation : Case series, histoimmunopathology, management, and review of the literature. In: Archives of Dermatology. 2006 ; Vol. 142, No. 2. pp. 206-210.
@article{f1232604998440ea9a84fec91c5b5367,
title = "Diltiazem induces severe photodistributed hyperpigmentation: Case series, histoimmunopathology, management, and review of the literature",
abstract = "Background: Diltiazem hydrochloride is a commonly prescribed benzothiazepine calcium channel blocker for the treatment of cardiovascular disease. Recently, 8 cases of diltiazem-induced photodistributed hyperpigmentation occurring predominantly in elderly African American women were reported. Here, we report occurrence for the first time in a light-skinned African American woman and a Hispanic woman. We also report this finding in an African American man. Biopsy specimens of hyperpigmented areas were obtained for histopathologic evaluation and marker studies. Photospectrometry analysis for diltiazem was performed to analyze the photoabsorption properties of this drug. Observations: Routine laboratory examination results were normal in all patients. Serologic test results for antinuclear antibodies, including Sj{\"o}gren antibodies anti-Ro (SS-A) and anti-La (SS-B), were negative. Histopathologic analysis of the skin biopsy specimens revealed a sparse lichenoid infiltrate, prominent pigmentary incontinence, and numerous melanophages in the dermis. There was no increase in dermal mucin suggestive of lupus. The mononuclear cells in the specimens were strongly positive for CD3, weakly positive for CD68, and either weakly positive or negative for CD79a. All specimens were negative for Alcian blue staining. Photospectrometry analysis of diltiazem showed an absorption range within the UV-B spectrum. Conclusions: Photospectrometry analysis revealed diltiazem could demonstrate a photosensitizing effect within the UV-B range. Discontinuation of therapy with diltiazem is the most effective modality in resolving hyperpigmentation. Avoidance of sun exposure and consistent use of sunscreens and sun-protective clothing are indicated for patients undergoing diltiazem therapy.",
author = "Saladi, {Rao N.} and Cohen, {Steven R.} and Phelps, {Robert G.} and Persaud, {Andrea N.} and Donald Rudikoff",
year = "2006",
month = "2",
doi = "10.1001/archderm.142.2.206",
language = "English (US)",
volume = "142",
pages = "206--210",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Diltiazem induces severe photodistributed hyperpigmentation

T2 - Case series, histoimmunopathology, management, and review of the literature

AU - Saladi, Rao N.

AU - Cohen, Steven R.

AU - Phelps, Robert G.

AU - Persaud, Andrea N.

AU - Rudikoff, Donald

PY - 2006/2

Y1 - 2006/2

N2 - Background: Diltiazem hydrochloride is a commonly prescribed benzothiazepine calcium channel blocker for the treatment of cardiovascular disease. Recently, 8 cases of diltiazem-induced photodistributed hyperpigmentation occurring predominantly in elderly African American women were reported. Here, we report occurrence for the first time in a light-skinned African American woman and a Hispanic woman. We also report this finding in an African American man. Biopsy specimens of hyperpigmented areas were obtained for histopathologic evaluation and marker studies. Photospectrometry analysis for diltiazem was performed to analyze the photoabsorption properties of this drug. Observations: Routine laboratory examination results were normal in all patients. Serologic test results for antinuclear antibodies, including Sjögren antibodies anti-Ro (SS-A) and anti-La (SS-B), were negative. Histopathologic analysis of the skin biopsy specimens revealed a sparse lichenoid infiltrate, prominent pigmentary incontinence, and numerous melanophages in the dermis. There was no increase in dermal mucin suggestive of lupus. The mononuclear cells in the specimens were strongly positive for CD3, weakly positive for CD68, and either weakly positive or negative for CD79a. All specimens were negative for Alcian blue staining. Photospectrometry analysis of diltiazem showed an absorption range within the UV-B spectrum. Conclusions: Photospectrometry analysis revealed diltiazem could demonstrate a photosensitizing effect within the UV-B range. Discontinuation of therapy with diltiazem is the most effective modality in resolving hyperpigmentation. Avoidance of sun exposure and consistent use of sunscreens and sun-protective clothing are indicated for patients undergoing diltiazem therapy.

AB - Background: Diltiazem hydrochloride is a commonly prescribed benzothiazepine calcium channel blocker for the treatment of cardiovascular disease. Recently, 8 cases of diltiazem-induced photodistributed hyperpigmentation occurring predominantly in elderly African American women were reported. Here, we report occurrence for the first time in a light-skinned African American woman and a Hispanic woman. We also report this finding in an African American man. Biopsy specimens of hyperpigmented areas were obtained for histopathologic evaluation and marker studies. Photospectrometry analysis for diltiazem was performed to analyze the photoabsorption properties of this drug. Observations: Routine laboratory examination results were normal in all patients. Serologic test results for antinuclear antibodies, including Sjögren antibodies anti-Ro (SS-A) and anti-La (SS-B), were negative. Histopathologic analysis of the skin biopsy specimens revealed a sparse lichenoid infiltrate, prominent pigmentary incontinence, and numerous melanophages in the dermis. There was no increase in dermal mucin suggestive of lupus. The mononuclear cells in the specimens were strongly positive for CD3, weakly positive for CD68, and either weakly positive or negative for CD79a. All specimens were negative for Alcian blue staining. Photospectrometry analysis of diltiazem showed an absorption range within the UV-B spectrum. Conclusions: Photospectrometry analysis revealed diltiazem could demonstrate a photosensitizing effect within the UV-B range. Discontinuation of therapy with diltiazem is the most effective modality in resolving hyperpigmentation. Avoidance of sun exposure and consistent use of sunscreens and sun-protective clothing are indicated for patients undergoing diltiazem therapy.

UR - http://www.scopus.com/inward/record.url?scp=33244458251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244458251&partnerID=8YFLogxK

U2 - 10.1001/archderm.142.2.206

DO - 10.1001/archderm.142.2.206

M3 - Article

C2 - 16490848

AN - SCOPUS:33244458251

VL - 142

SP - 206

EP - 210

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 2

ER -